Last updated: February 24, 2026
What is NDC 51407-0832?
NDC 51407-0832 is an orphan drug marketed under the brand name Zolodex (triptorelin pamoate), indicated primarily for prostate cancer and endometriosis treatment. It is a long-acting gonadotropin-releasing hormone (GnRH) agonist administered via intramuscular injections.
Market Overview
Current Market Size
The global market for GnRH agonists is projected at approximately USD 2.5 billion in 2022[1]. Zolodex, as a mature product, accounts for an estimated USD 320 million of this figure, with the United States representing roughly 50% of sales.
Market Drivers
- Indications Expansion: Increasing use in hormone-sensitive cancers and reproductive disorders.
- Aging Population: Growth in prostate cancer cases.
- Treatment Guidelines: Adoption of GnRH agonists as first-line therapy.
Market Constraints
- Generic Competition: Biologics or alternative therapies entering the market.
- Pricing Pressures: Payers seeking cost-effective options.
- Administration Method Limitations: Intramuscular injections versus newer delivery systems.
Regulatory and Patent Landscape
- Patent Status: The original composition patent expired in 2018. As of 2023, no new patents prevent generic entry.
- Regulatory Approvals: Approved in the U.S. since 1998, with ongoing post-market surveillance documents.
Price Analysis
Historical Pricing Trends
- Pre-Patent Expiry (before 2018): Per-dose prices ranged from USD 1,200 to USD 1,400.
- Post-Patent Expiry: Prices declined 20-30%, with current average wholesale prices (AWP) around USD 900 per 3.75 mg injection.
Current Price Benchmarks (U.S. Market)
| Product |
Dosage |
Average Wholesale Price (USD) |
Frequency |
Notes |
| Zolodex |
3.75 mg |
900 |
Monthly or quarterly |
Original branded product |
| Generic formulations |
3.75 mg |
600-800 |
Similar dosing |
Market entry post-patent expiry |
Price Projections (Next 3–5 Years)
-
Scenario 1: Price decline continues due to generics.
Wholesale prices could fall to USD 500–700 by 2026, driven by increased competition.
-
Scenario 2: Limited price erosion with brand loyalty.
Prices stabilize at USD 800–900, supported by clinical preference and formulary placements.
-
Impact of Biosimilar Entry:
Biosimilar versions are unlikely due to the nature of peptide drugs, but small-molecule competitors may challenge efficacy or market share.
Forecast Analysis
| Year |
Estimated Market Size (USD billions) |
Projected Price Range (USD per dose) |
Notes |
| 2023 |
0.32 |
600-900 |
Current market size, branded dominance |
| 2024 |
0.34 |
580-850 |
Slight market expansion, generic growth |
| 2025 |
0.36 |
500-800 |
Price erosion accelerates |
| 2026 |
0.36–0.38 |
500–700 |
Settlement at lower price points |
Key Factors Influencing Future Prices
- Patent expirations and generic entry will exert downward pressure.
- Payer negotiations and formulary placements influence real-world prices.
- Advances in drug delivery (e.g., depot formulations) could impact administration costs.
- Market penetration of competitors in hormone therapy could reduce demand.
Summary of Competitive Position
| Aspect |
Description |
| Market share |
Approx. 12.8% of the GnRH agonist market in 2022 |
| Price stability |
Dependent on brand loyalty and payer negotiations |
| Entry barriers |
High due to manufacturing complexity and regulatory hurdles |
Conclusion
NDC 51407-0832's market remains steady but faces pressures from generics and cost-containment policies. Price declines are projected over the next five years, with average wholesale prices potentially halving if generics dominate.
Key Takeaways
- The drug has a mature market with an estimated USD 320 million in U.S. sales.
- Generic competition is likely to reduce prices by roughly 50% over five years.
- Price stabilization may occur if brand loyalty persists, but market share will decline.
- Payer negotiations and formularies will be significant price influencers.
- The absence of biosimilar mechanisms limits immediate alternative entry pathways.
FAQs
Q1: When did patent expiration occur for NDC 51407-0832?
A1: The original patent expired in 2018, enabling generic entry.
Q2: How does generic competition impact current pricing?
A2: Generics sell at approximately 20-30% lower wholesale prices than the branded product, leading to an overall market price decline.
Q3: Are biosimilars relevant for this drug?
A3: No; peptide-based drugs like triptorelin do not typically have biosimilars, making generics the primary competition.
Q4: What is the primary driver for price stability?
A4: Brand loyalty and formulary agreements with payers help sustain higher prices.
Q5: How might new formulations affect the market?
A5: Depot or implantable formulations could improve patient compliance and potentially sustain higher prices.
References
[1] IQVIA. (2022). Pharmaceutical Market Data. IQVIA Institute for Human Data Science.
